Traditional cardiovascular risk factors do not entirely account for the increased risk of atherosclerosis, the major cause of death, in systemic lupus erythematosus (SLE). In this project we want to identify new pathogenic pathways of atherosclerosis in SLE patients, by assessing the association between newly identified potential risk factors and a refined measure of subclinical atherosclerosis, soft (noncalcified) coronary plaque. Similarly over 50% of SLE patients develop lupus nephritis, including 75% of African-American SLE patients. Renal biopsy is the gold standard to determine renal activity, but is expensive, invasive, and has real risk to the patient. We hypothesize that urinary markers of renal activity will have clinical utility in human lupus nephritis, as they have in renal transplant patients and murine models of SLE. In addition we want to develop and study three new approaches to assess hypercoagulability risk (endogenous thrombogenic potential, complement activation, and platelet microparticles) to determine if these markers can predict future thrombotic events or associated with antiphospholipid antibodies.

Public Health Relevance

Although the survival of SLE patients has greatly improved, permanent organ damage continues to occur in the general public. This project addresses three challenges: hardening of the arteries, blood clots, and lupus kidney disease in collaboration with other rheumatologists and radiologists.

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Research Project (R01)
Project #
Application #
Study Section
Cardiovascular and Sleep Epidemiology (CASE)
Program Officer
Witter, James
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Costedoat-Chalumeau, Nathalie; Houssiau, Frédéric; Izmirly, Peter et al. (2017) A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. Clin Pharmacol Ther :
Stojan, G; Petri, M (2017) The risk benefit ratio of glucocorticoids in SLE: have things changed over the past 40 years? Curr Treatm Opt Rheumatol 3:164-172
Bernatsky, S; Ramsey-Goldman, R; Petri, M et al. (2017) Breast cancer in systemic lupus. Lupus 26:311-315
Duarte-García, Alí; Barr, Erik; Magder, Laurence S et al. (2017) Predictors of incident proteinuria among patients with SLE. Lupus Sci Med 4:e000200
Abou Assalie, Nour; Durcan, Robert; Durcan, Laura et al. (2017) Hydroxychloroquine-Induced Erythema Multiforme. J Clin Rheumatol 23:127-128
Györi, Noémi; Giannakou, Ioanna; Chatzidionysiou, Katerina et al. (2017) Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort. Lupus Sci Med 4:e000192
Buyon, Jill P; Kim, Mimi Y; Guerra, Marta M et al. (2017) Kidney Outcomes and Risk Factors for Nephritis (Flare/De Novo) in a Multiethnic Cohort of Pregnant Patients with Lupus. Clin J Am Soc Nephrol 12:940-946
Eudy, A M; Siega-Riz, A M; Engel, S M et al. (2017) Gestational weight gain in women with systemic lupus erythematosus. Lupus 26:623-632
Khan, Aisha; Arbab-Zadeh, Armin; Kiani, Adnan N et al. (2017) Progression of noncalcified and calcified coronary plaque by CT angiography in SLE. Rheumatol Int 37:59-65
Baer, Alan N; Petri, Michelle; Sohn, Jungsan et al. (2017) Reply. Arthritis Care Res (Hoboken) 69:454

Showing the most recent 10 out of 194 publications